Active Litigation
Nitrous Oxide Lawsuit Facts
TorHoerman Law is actively accepting claims for the Nitrous Oxide Lawsuit.
Active Litigation
TorHoerman Law is actively accepting claims for the Nitrous Oxide Lawsuit.
A nitrous oxide deep vein thrombosis lawsuit may involve allegations that recreational nitrous oxide exposure contributed to a serious blood clot in a deep vein.
Medical reports describe deep vein thrombosis (DVT), pulmonary embolism, and other thrombotic events in people who repeatedly inhaled nitrous oxide.
One suspected pathway involves nitrous oxide interfering with vitamin B12 activity and causing unusually high homocysteine levels, although other causes of blood clots must also be considered.
We are investigating potential claims involving DVT and related blood clot injuries allegedly associated with inadequate warnings about recreational nitrous oxide use.

Deep vein thrombosis occurs when a blood clot forms in a deep vein, usually in the leg or pelvis.
It may cause swelling, pain, tenderness, or warmth in the affected limb, but some people have no recognizable symptoms.
A portion of the clot can detach and travel to the lungs, producing a pulmonary embolism that may be life-threatening.
Researchers have reported these complications in younger adults with histories of heavy recreational nitrous oxide inhalation, sometimes alongside neurological symptoms of vitamin B12 dysfunction.
Leg and pelvic DVT with pulmonary embolism have been documented after heavy nitrous oxide exposure, but their frequency among all users is unknown.
Imaging can confirm a clot, while its cause requires consideration of nitrous oxide exposure, medical history, and other risk factors.
A nitrous oxide lawsuit involving a blood clot may depend on the specific product used, its warnings, and medical evidence connecting exposure to the injury.
Recreational nitrous oxide use has been associated with venous thrombosis in clinical cases and hospital studies, including DVT and pulmonary embolism.
Repeated exposure can impair vitamin B12 function and raise homocysteine, a substance involved in normal amino acid metabolism.
The evidence connecting this process to DVT comes mainly from hospital-based observations, case reports, and reviews of those reports.
It does not provide a reliable estimate of the absolute risk of DVT among nitrous oxide users or establish that nitrous oxide caused every clot reported after exposure.
Medical nitrous oxide is administered with oxygen under clinical supervision.
Inhalation from chargers or tanks can involve repeated, unmeasured exposure.
A person who develops DVT may also have risk factors such as recent surgery, prolonged immobility, inherited thrombophilia, pregnancy, estrogen-containing medication, cancer, or a previous blood clot.
These possible contributors require assessment even when nitrous oxide exposure and elevated homocysteine are documented.
Nitrous oxide can inactivate vitamin B12 and inhibit methionine synthase, an enzyme involved in converting homocysteine to methionine.
Disruption of these metabolic pathways can lead to elevated homocysteine levels, a condition called hyperhomocysteinemia.
Severe elevations have been documented in patients who experienced thrombotic events following heavy recreational inhalation.
Researchers have proposed that high homocysteine may contribute to endothelial dysfunction, platelet activation, and impaired fibrinolysis, the process by which the body breaks down clots.
These mechanisms could contribute to abnormal clot formation, but a high homocysteine result cannot independently establish why a patient developed DVT.
Functional vitamin B12 deficiency may occur even if a routine serum B12 measurement falls within the laboratory reference range.
In selected patients, homocysteine and methylmalonic acid testing may help clinicians identify functional B12 disruption after nitrous oxide exposure.
Repeated exposure can also cause peripheral neuropathy and spinal cord damage, including subacute combined degeneration, with symptoms such as muscle weakness and numbness.
These forms of nerve damage can occur alongside DVT, but they do not establish that a blood clot is present.
DVT is a clot in a deep vein, whereas a pulmonary embolism is a blockage in the pulmonary arteries, often caused by a clot that traveled from the veins of the legs or pelvis.
Together, DVT and pulmonary embolism are forms of venous thromboembolism (VTE).
Arterial thrombosis involves a clot in an artery supplying an organ or limb and may cause conditions such as a heart attack or stroke.
Studies of nitrous oxide exposure sometimes group venous and arterial clots together, even though they occur in different parts of the circulation.
A diagnosis of pulmonary embolism does not automatically mean clinicians identified the original DVT, and an arterial clot should not be classified as DVT.
Published research documents serious thrombotic events in patients who reported recreational nitrous oxide use, but the available samples are selected clinical populations rather than representative groups of all users.
A 2018 case report described an aortic arch thrombus followed later by DVT and pulmonary embolism in a patient with recurrent nitrous oxide use.
The authors considered exposure a possible contributor, but the patient also had a factor II mutation, and the report could not establish the cause of each clot.
The aortic arch thrombus was an arterial clot; the DVT developed later in a deep vein.
A study published in the Journal of Thrombosis and Haemostasis reviewed 326 patients at an Amsterdam hospital who reported recreational nitrous oxide use between January 2015 and May 2021.
Researchers identified 17 patients with serious thrombotic events, including 12 venous events and five arterial events.
Among the 17 patients with thrombotic events, the researchers reported:
The 12 venous events included pulmonary, portal-vein, and cerebral-vein clots, rather than 12 confirmed leg DVT cases.
Seventeen of 326 patients, about 5% of this selected hospital group, had serious thrombotic events; the study cannot establish the rate among all recreational nitrous oxide users.
The authors identified severe hyperhomocysteinemia as a recurring finding and recommended greater recognition of possible thromboembolic complications.
A Royal London Hospital case series identified four patients with recent or concurrent unprovoked venous thromboembolism among 50 patients seen through a pathway for nitrous oxide-related neurological presentations from March through August 2023.
Two of the four had both pulmonary embolism and DVT, one had pulmonary embolism, and one had cerebral venous sinus thrombosis.
Four of the 50 patients in this selected clinical pathway, or 8%, had VTE; the study did not sample recreational nitrous oxide users in the general population.
A November 2024 case report in the International Journal of Emergency Medicine described a 23-year-old patient who developed a blood clot in the right iliac vein and pulmonary emboli in both lungs.
He reported nitrous oxide use during the preceding month, along with alcohol and cannabis.
The patient initially presented with abdominal pain, vomiting, diarrhea, fever, and other signs of illness rather than classic calf symptoms alone.
CT imaging identified the pelvic clot and bilateral pulmonary embolism.
His homocysteine was 51.9 μmol/L, and methylmalonic acid was also elevated, suggesting disrupted B12-dependent metabolism.
He received anticoagulation, initially with enoxaparin and then rivaroxaban, and improved during treatment.
The authors considered nitrous oxide a possible contributor, while noting inflammation, dehydration, concurrent substance use, and other clinical circumstances that complicated causal interpretation.
A 2025 case report published in Cureus described a 31-year-old man with ongoing nitrous oxide use who developed a right-leg DVT and a saddle pulmonary embolism.
He sought treatment for shortness of breath and calf pain, and testing showed low vitamin B12 and elevated homocysteine.
A saddle pulmonary embolism straddles the division of the main pulmonary artery into its branches, although clinical severity depends on how the clot affects blood flow and heart function.
The patient received anticoagulation and was discharged in stable condition.
A review published in Annals of Vascular Surgery in September 2026 identified 18 studies describing more than 40 thrombotic events temporally associated with recreational nitrous oxide use.
The reports included DVT, pulmonary embolism, cerebral venous thrombosis, stroke, acute limb ischemia, and aortic clots.
Researchers frequently observed elevated homocysteine, sometimes despite normal serum vitamin B12 levels.
Because the review drew from published clinical reports, it could not estimate the rate of blood clots among all users or determine whether nitrous oxide caused each event.
Its reported events included both venous and arterial clots.
DVT symptoms after nitrous oxide exposure generally resemble symptoms of a clot caused by other risk factors.
A clot most commonly develops in the lower extremities, although pelvic and upper-extremity veins can also be affected.
Possible signs of DVT include:
Approximately half of people with DVT have no symptoms.
A person may therefore develop a pulmonary embolism without first noticing leg pain or swelling.
These symptoms can also result from muscle injury, inflammation, or infection, so clinical evaluation and imaging are needed to determine whether a clot is present.
Seek prompt medical assessment for unexplained leg swelling or pain, particularly when there has been recent nitrous oxide inhalation.
A pulmonary embolism can occur when a clot breaks away from a deep vein and becomes lodged in an artery supplying the lungs.
The resulting obstruction can impair blood flow and oxygen delivery, sometimes causing serious strain on the heart.
Call 911 for symptoms suggesting a pulmonary embolism, including:
A pulmonary embolism is a medical emergency, even when no leg clot was previously diagnosed.
A patient may have a pulmonary embolism without visible leg swelling.
In the emergency department, clinicians first assess vital signs, blood pressure, oxygen saturation, symptoms, and the patient’s history while determining whether urgent imaging is needed.
The evaluation then addresses two different questions: whether a blood clot is present and what factors may have contributed to its formation.
Neither a history of nitrous oxide use nor a high homocysteine level can replace imaging needed to establish DVT or pulmonary embolism.
Tests used in the evaluation may include:
A positive D-dimer alone does not confirm DVT because it can rise for many reasons.
A normal ultrasound result may require reassessment or repeat imaging if clinical suspicion remains high, depending on the diagnostic approach.
Because other conditions can cause similar symptoms, specialized imaging is needed to diagnose DVT or pulmonary embolism.
When nitrous oxide-related B12 deficiency is suspected, NICE recommends plasma homocysteine or serum methylmalonic acid as an initial test.
Serum vitamin B12 can fall within the reference range even when repeated exposure has disrupted its function.
These results may support evidence of functional B12 disruption, but they do not reveal whether a clot is present or definitively attribute its cause to nitrous oxide.
Other possible contributors clinicians may consider include:
Even when homocysteine is elevated, other clotting risk factors require assessment.
Thrombophilia screening, including tests for antiphospholipid antibodies or lupus anticoagulant when appropriate, is a selective part of the differential diagnosis; testing every patient for every inherited disorder is not routinely necessary.
If vitamin B12 deficiency is found, clinicians may separately consider causes such as pernicious anemia; that evaluation does not replace the assessment of clot risk factors.
Treatment of a confirmed clot generally follows established approaches for venous thromboembolism rather than a separate, proven nitrous oxide-specific treatment protocol.
Doctors also address suspected functional B12 deficiency and advise stopping recreational nitrous oxide exposure.
Anticoagulants, often called blood thinners, reduce the risk of a clot growing or new clots forming while the body gradually breaks down the existing clot.
Depending on the patient’s medical condition, clinicians may use apixaban, rivaroxaban, heparin, enoxaparin, or other anticoagulants.
Treatment options may include:
The length of anticoagulation depends on the clot location, recurrence risk, bleeding risk, and whether clinicians consider the event provoked by a temporary factor or associated with a continuing risk.
Treatment commonly continues for several months, and some patients require longer-term anticoagulation.
Patients should not stop or change prescribed blood thinners without medical guidance.
When nitrous oxide-related B12 dysfunction is suspected, treatment includes stopping exposure and addressing the deficiency.
Clinicians may recommend vitamin B12 replacement by mouth or injection, depending on the patient’s condition, and follow-up testing when appropriate.
In a 2026 study of hospitalized patients with nitrous oxide-related neurological injury, homocysteine declined rapidly after admission and reached the normal range at approximately one week; the study did not measure how quickly DVT risk changed.
Vitamin B12 supplementation does not dissolve an existing DVT or replace anticoagulant treatment.
Continued nitrous oxide inhalation can interfere with B12 function despite supplementation, so complete cessation remains necessary to address ongoing exposure.
People who have difficulty stopping repeated inhalant use may also need substance-use treatment and follow-up care.
Some patients recover from DVT without persistent symptoms after appropriate treatment.
Others experience ongoing vascular complications even after the original clot has been treated.
Potential complications include:
Follow-up may address the duration of anticoagulation, symptoms of bleeding, repeat clot risks, and persistent leg or respiratory symptoms.
Neither a patient’s age nor improvement in homocysteine guarantees that a subsequent clot cannot occur.
A prior DVT increases the importance of evaluating recurrence risk, even if nitrous oxide exposure has ended.
Stopping exposure removes one suspected contributing factor, but the available studies do not quantify how much cessation changes the risk of another clot.
Decisions about discontinuing anticoagulation depend on the complete clinical picture, including other clotting risk factors and whether an ongoing cause is suspected.
New leg swelling, pain, chest symptoms, or shortness of breath require medical attention rather than an assumption that a previous clot has resolved permanently.
A warning about general nitrous oxide risks does not determine whether a particular manufacturer’s warnings were legally inadequate or whether a specific exposure caused an individual’s DVT.
Our attorneys are reviewing potential claims involving diagnosed DVT, pulmonary embolism, and associated injuries following recreational nitrous oxide use.
Relevant medical information includes the imaging-confirmed clot, exposure history, B12-related laboratory results, treatment course, and other identified thrombotic risk factors.
The product’s identity, labeling, and sales circumstances may bear on whether a warning claim is viable.
Call TorHoerman Law today for a free consultation, or use our chat feature to discuss a potential claim.
Published cases describe DVT, pulmonary embolism, and other thrombotic events in younger adults who reported heavy recreational nitrous oxide use.
However, age and apparent health do not rule out other clotting risks, and the studies do not establish that nitrous oxide caused every event or provide a general population risk estimate.
No.
High homocysteine may support a suspected disturbance in vitamin B12-dependent metabolism, but it cannot independently establish a clot or identify the sole cause of one.
Imaging and assessment of other risk factors remain necessary.
Yes.
About half of people with DVT have no symptoms, and a pulmonary embolism can occur without a previously recognized leg clot.
Unexplained chest pain, breathing difficulty, or fainting requires emergency assessment even in the absence of leg symptoms.
No.
B12 replacement may be appropriate for suspected functional deficiency, but an established DVT or pulmonary embolism requires evaluation and treatment according to accepted venous thromboembolism protocols.
Anticoagulation is commonly used, with additional procedures reserved for selected serious cases.
No.
DVT is a clot within a deep vein, while pulmonary embolism is a blockage in the arteries of the lungs, often caused by a clot that moved from a deep vein.
They are related forms of venous thromboembolism but can require different diagnostic imaging and emergency treatment.
It can.
Some people develop post-thrombotic syndrome, recurring clots, or lasting complications after a pulmonary embolism, although many recover without major long-term impairment.
The prognosis depends on the severity and location of the clot, treatment, and the patient’s other medical risks.
Clinicians assess the full exposure history alongside surgery, immobility, estrogen use, prior clotting events, medical conditions, and other recognized risks.
Someone taking an estrogen-containing medication should tell their treating clinician about nitrous oxide use and discuss their individual clot risk rather than stop prescribed medication without advice.
A history of nitrous oxide use and abnormal B12-related testing may contribute to the assessment, but neither automatically excludes another explanation for the blood clot.

Tor Hoerman has represented injured individuals for more than 30 years, with experience spanning individual personal injury cases and nationwide mass tort litigation. His work includes car accidents, catastrophic injuries, product liability claims, and other serious injury cases. Tor has served in court-appointed leadership roles in national litigation and tried cases involving major corporate defendants.
TorHoerman Law’s legal content is researched and written by our editorial team and attorneys for legal accuracy, clarity, and relevance. We rely on statutes, court records, government publications, medical research, and other authoritative sources when applicable. This page provides general legal information and does not constitute legal advice.
TorHoerman Law reviews its legal content for factual accuracy, current information, and relevant legal context before publication and as material developments occur. This article is provided for general informational purposes and does not constitute legal advice. For guidance about a specific case, contact TorHoerman Law.
You can learn more about this topic by visiting any of our Nitrous Oxide Lawsuit pages listed below:
A serious injury can change your life.

TorHoerman Law represents people whose lives have been disrupted by serious injuries, unsafe products, and negligence. Our attorneys handle individual personal injury cases as well as national mass tort lawsuits involving major corporations.
Founded in 2009, our legal team brings more than 100 years of combined experience handling serious injury and complex civil litigation.
Do you believe you’re entitled to compensation?
Use our Instant Case Evaluator to find out in as little as 60 seconds!

In this case, we obtained a verdict of $495 Million for our client’s child who was diagnosed with Necrotizing Enterocolitis after consuming baby formula manufactured by Abbott Laboratories.

In this case, we were able to successfully recover $20 Million for our client after they suffered a Toxic Tort Injury due to chemical exposure.

In this case, we were able to successfully recover $103.8 Million for our client after they suffered a COX-2 Inhibitors Injury.

In this case, we were able to successfully recover $4 Million for our client after they suffered a Traumatic Brain Injury while at daycare.

In this case, we were able to successfully recover $2.8 Million for our client after they suffered an injury due to a Defective Heart Device.
A serious injury can change your life.